Please login to the form below

Not currently logged in
Email:
Password:

Zoetis

This page shows the latest Zoetis news and features for those working in and with pharma, biotech and healthcare.

Pfizer mulling product sale to streamline ops; sources

Pfizer mulling product sale to streamline ops; sources

unit Zoetis to deal with accretion and dilution.

Latest news

More from news
Approximately 2 fully matching, plus 26 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2014 Pharma deals during November 2014

    form of Zoetis who this month acquired Abbott's animal health business for $255m. ... Bill Ackman, a Valeant investor, now owns 8.5% of Zoetis, which may pave the way for a potential deal.

  • Pharma deals during April 2014 Pharma deals during April 2014

    spot in terms of sales, second only to Zoetis.

  • Pharma deals during January 2014 Pharma deals during January 2014

    Several major pharma firms are deciding where to focus their business interests with Pfizer spinning out Zoetis for its animal health interests and Abbott doing the same for its pharma business,

  • Pharma deals during December 2012 Pharma deals during December 2012

    The next major event in the animal health deal calendar will probably be the IPO of Pfizer's animal health business (named in the IPO documents as Zoetis) which had 2011

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Random42 Scientific Communication

    Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for over 550 product launches for the world's leading pharmaceutical, biotechnology and medical companies and won over 150

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
McCann Complete Medical

Complete Medical delivers world-class solutions in medical communications, regulatory services, healthcare multichannel excellence, and strategic consultancy. We bring together specialist...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics